Your search history is turned on.
Date: May 3, 2024 16:42:40 EST Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
2024 DEFA14A U.S. Notice and Access Card May 3 2024-2024-05-03-15-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 __________________________________________________ Filed by the Regi...
Date: May 3, 2024 16:41:41 EST Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Form of Proxy - Annual General Meeting to be held on Friday, June 14, 2024 01ZS8D This Form of Proxy is solicited by and on behalf of Management and the Board of Directors. Fold Fold CONTROL NUMBER To vote by telephone or the Internet, you will need to provide your CONTROL NUMBER listed below. If you vote by telephone or the Internet, DO NOT mail back this prox...
Date: May 3, 2024 16:41:08 EST Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Aurinia Pharmaceuticals Inc. 2024 Definitive Proxy UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 __________________________________________________ Filed by the Registrant ...
Date: May 3, 2024 16:40:09 EST Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
ExtractPage3 ...
Date: May 2, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Q1 2024 10-Q-2024-05-01-20-41 Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Miller, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..; 2. Based on my knowledge, this report doe...
Q1 2024 10-Q-2024-05-01-20-41 Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Peter Greenleaf, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.; 2. Based on my knowledge, this...
Q1 2024 10-Q-2024-05-01-20-41 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION R...
2024 Q1 8K-2024-05-01-20-45 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-3...
Microsoft Word - a53971031-release.htm Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in ...